Enamel of the teeth is the most solid material in your whole body, even harder than bones. However, there is only a limited amount of it. When it disappears, your body will be unable to produce new enamel, and that is why enamel erosion is such an insidious and serious problem for millions of people. […]
The post Understanding Tooth Enamel Erosion: Causes, Risks, and Treatment Options appeared first on Medical News Bulletin.
Looking for impartial information on taxifolin AKA Dihydroquercetin? Learn about this potent antioxidant and it’s potential as a nutraceutical or dietary supplement with MNB. What is Taxifolin? Taxifolin AKA Dihydroquercetin is a bioactive compound in the flavonoid family. Plants naturally produce flavonoids as part of their cellular defences to protect their DNA from mutations and […]
The post Navigating Nutraceuticals: Taxifolin appeared first on Medical News Bulletin.
Digital health is revolutionizing mental health. Psychiatric providers are already using telehealth, online intake forms, electronic health records, symptom-monitoring apps, remote-monitoring devices, digital therapeutics, artificial intelligence (AI) tools for documentation, and secure messaging. This is not a trend for psychiatric mental health nurse practitioners. It is here now. So, a DNP PMHNP program cannot only educate nurses […]
The post Are DNP PMHNP Programs Preparing Nurses for Digital Mental Health Tools? appeared first on Medical News Bulletin.
The FDA has approved the first proteolysis-targeting chimera for any oncologic indication.
Vepdegestrant (Veppanu, Arvinas Operations) — a heterobifunctional protein degrader — received approval for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test, according to an FDA press release.
The indication applies to patients with disease progression after endocrine therapy.
The agency based its decision on the randomized, phase 3 VERITAC-2 study, which showed a 43% risk reduction for disease progression with the agent,